Quick Answer
Lysoveta® is a krill-derived ingredient developed by Aker BioMarine that delivers DHA — and a smaller amount of EPA — in the lysophosphatidylcholine (LPC) form. LPC-DHA is the molecular form recognised by MFSD2A, the brain's dedicated DHA transporter at the blood-brain barrier. Nutrascience Neuro+ LPC delivers Lysoveta to Southeast Asia, paired with Revervia® algal DHA in a dual-pathway formulation. Now shipping to Malaysia, Singapore, Hong Kong, and Bangkok at nutrascience.co/products/neuro-lpc.
Most people who take omega-3 supplements assume the DHA in their capsule ends up in their brain. The biology is more complicated than that — and it is the reason Nutrascience built Neuro+ LPC around Lysoveta rather than another generic fish oil.
DHA (docosahexaenoic acid) is the dominant structural fatty acid in the human brain. It supports neuronal membrane integrity and synaptic signalling, and contributes to the maintenance of normal brain function. The challenge is not whether your supplement contains DHA. Most do. The real question is whether the DHA in that supplement can actually reach the brain in meaningful concentrations.
That is the problem the Lysoveta inside Nutrascience Neuro+ LPC was designed to address.
What Is Lysoveta, and Why Did Nutrascience Build Neuro+ LPC Around It?
Lysoveta is a krill-derived ingredient developed by Aker BioMarine, launched in November 2020 as the world's first commercially available source of LPC-bound omega-3s. It is backed by 40 patents across 16 countries and remains the only LPC-EPA/DHA ingredient currently produced at scale.
Manufactured from Antarctic krill, Lysoveta is molecularly distinct from conventional krill oil and fish oil. Its primary contribution is LPC-DHA — the lysophospholipid form of DHA recognised by the brain's MFSD2A transporter. It also delivers a smaller portion of LPC-EPA, which has its own role in brain delivery and can convert to DHA in brain tissue.
Nutrascience Neuro+ LPC is built around the LPC-DHA mechanism. Each two-softgel serving delivers Lysoveta alongside Revervia® algal DHA — a dual-pathway design that addresses both brain-targeted DHA delivery and systemic omega-3 status in one formulation.
Why DHA Form Matters More Than DHA Dose
The omega-3 industry has historically competed on quantity — higher EPA, higher DHA, higher milligrams per serving. What this framing misses is foundational: the molecular form of DHA determines where in the body it is distributed, not just how much is absorbed.
There are three primary dietary forms of DHA:
- Triglyceride (TG) DHA — found in most fish oils. Absorbed systemically and distributed primarily to plasma, liver, heart, and adipose tissue.
- Phospholipid (PL) DHA — found in standard krill oil. Improved systemic bioavailability compared to triglycerides, but still limited in brain-specific delivery.
- Lysophosphatidylcholine DHA (LPC-DHA) — the form delivered by Lysoveta inside Nutrascience Neuro+ LPC. The form recognised by MFSD2A, the brain's dedicated DHA transporter.
Taking more DHA in the wrong form does not solve the brain-delivery problem. It addresses systemic omega-3 status, which has value — but it is not the same thing as brain-targeted DHA nutrition. This is why Nutrascience designed Neuro+ LPC around form, not dose.
How Does the Blood-Brain Barrier Limit Standard Omega-3s?
The blood-brain barrier (BBB) is a highly selective membrane that separates circulating blood from the brain's extracellular fluid. Its job is protective: it blocks pathogens, toxins, and the vast majority of molecules — including most nutrients — from entering the brain freely.
For DHA to reach the brain, it must pass through this barrier via specific, regulated mechanisms. Standard triglyceride-form DHA is not efficiently transported across the BBB. It circulates systemically, enters tissues that lack such a barrier, and contributes to whole-body omega-3 levels — but it does not reliably enrich brain DHA.
This is not a product defect. It is a biological constraint that applies to every standard fish oil supplement on the market, regardless of dose or purity. The Lysoveta in Nutrascience Neuro+ LPC is a formulation-level answer to that constraint.
What Is MFSD2A and Why Does It Matter for Brain DHA?
In 2014, a research team led by Long N. Nguyen, with senior author David L. Silver of Duke-NUS Medical School in Singapore, published a landmark paper in Nature identifying MFSD2A (Major Facilitator Superfamily Domain Containing 2A) as the major transporter responsible for moving DHA across the blood-brain barrier into the brain.
The significance was not just identifying the transporter. It was what the transporter would and would not accept.
MFSD2A is structurally selective for DHA bound in the LPC form. Triglyceride-form DHA — the kind found in virtually all standard fish oil supplements — is not transported by this pathway. It does not carry the molecular structure MFSD2A is designed to bind. (LPC-EPA can also be transported by MFSD2A, and a portion is converted to DHA in brain tissue — but LPC-DHA is the direct delivery form.)
The brain has a dedicated, highly specific channel for importing DHA. The question every brain-supplement buyer should ask is whether the DHA in their capsule is in the right form to use it. The Lysoveta inside Nutrascience Neuro+ LPC is.
How Is Lysoveta Different from Krill Oil and Fish Oil?
This distinction matters commercially because krill oil is often marketed as superior to fish oil due to its phospholipid content. That is a meaningful advantage for systemic absorption. However, standard krill oil phospholipids are primarily phosphatidylcholine (PC) DHA — not lysophosphatidylcholine (LPC) DHA.
PC and LPC are structurally different molecules. PC-DHA is not transported by MFSD2A in the same way LPC-DHA is. The lysophospholipid form — with one fatty acid chain removed — is the specific structure the MFSD2A pathway recognises.
Lysoveta is produced by Aker BioMarine specifically to deliver LPC-bound omega-3s — primarily LPC-DHA, with some LPC-EPA. That is the molecular precision Nutrascience selected for Neuro+ LPC, and what separates it from conventional krill phospholipid products on the market.
| DHA Source | Primary Form | MFSD2A-Compatible | Primary Distribution |
|---|---|---|---|
| Fish Oil | Triglyceride | No | Systemic (plasma, liver, adipose) |
| Standard Krill Oil | Phosphatidylcholine | Limited | Systemic with improved bioavailability |
| Lysoveta® (in Nutrascience Neuro+ LPC) | Lysophosphatidylcholine (LPC-DHA, with LPC-EPA) | Yes | Brain-targeted via MFSD2A |
| Algal DHA (Revervia® — also in Neuro+ LPC) | Triglyceride / Free DHA | No | Systemic omega-3 support |
What Does the Research Say About LPC-DHA Brain Uptake?
The primary human-relevant evidence for LPC-DHA brain uptake is mechanistic — based on the established biology of the MFSD2A transporter (Nguyen et al., 2014, Nature) and supported by preclinical data.
A key study by Sugasini et al. (2017), published in Scientific Reports, examined how different DHA forms affected brain DHA enrichment. In normal mice gavaged with equal doses (10 mg DHA/day for 30 days), DHA from triglyceride sources was incorporated preferentially into adipose tissue and heart but not brain. In contrast, LPC-DHA increased brain DHA by up to 100%.
This is consistent with the established MFSD2A mechanism: if the transporter is selective for LPC-DHA, providing DHA in that form should result in a meaningfully different brain distribution compared to forms the transporter does not preferentially accept.
It is appropriate to note that the animal model findings have not yet been replicated in a large-scale randomised human trial. The mechanistic foundation is well-established; clinical translation continues to be studied. Nutrascience designed Neuro+ LPC to reflect both what the science currently supports and what it does not yet claim — which is why we publish the evidence tier alongside the formula.
How Is Lysoveta Used Inside Nutrascience Neuro+ LPC?
Lysoveta is a precision ingredient. Because it is derived from Antarctic krill, it carries a natural shellfish allergen profile and is not suitable for individuals with seafood allergies. It is also not a vegan ingredient.
In Nutrascience Neuro+ LPC, Lysoveta is combined with Revervia® algal DHA in a dual-pathway design:
- Lysoveta addresses brain-targeted DHA delivery via the MFSD2A transporter and contributes LPC-EPA as a secondary input.
- Revervia provides systemic DHA to support whole-body omega-3 adequacy.
These are complementary biological roles, not a synergistic molecular interaction. Each Neuro+ LPC serving is two softgels, with bovine gelatin capsules.
Every ingredient is named, dosed, and verified. The full Nutrascience Standard applies: fully-disclosed formula, science-backed mechanism, 100% traceable sourcing, third-party tested, and GMP-manufactured. No proprietary blends. No undisclosed doses.
Who Is Nutrascience Neuro+ LPC Designed For?
Nutrascience Neuro+ LPC is designed for people who demand science first, who read the label before they read the marketing.
If you have already moved past generic fish oil — if you have noticed that "1000mg omega-3" tells you almost nothing about what reaches your brain, and that "proprietary blend" tells you even less about what you are actually paying for — you are the person Neuro+ LPC was formulated for.
Specifically:
- People who value full ingredient disclosure over branded blends and unnamed doses. Every ingredient in Neuro+ LPC is named, dosed, and verified.
- People who choose science-backed mechanisms over trend-led marketing. No nootropic stacks chosen for buzz. No megadosing. The Lysoveta in Neuro+ LPC is included because the MFSD2A pathway is real, peer-reviewed, and specific.
- Adults who want to support cognitive function over the long term — particularly through the 40+ decades when brain DHA status becomes a meaningful variable in healthy ageing, and for their ageing parents.
- Existing omega-3 users who recognise that systemic omega-3 levels and brain-targeted DHA delivery are not the same thing, and want a formulation that addresses both.
- Cognitively demanding professionals and teens across Singapore, Hong Kong, Kuala Lumpur, and Bangkok who treat supplementation as infrastructure, not optimism.
Nutrascience does not formulate for trends, for proprietary blends, or for the largest possible audience. We formulate for the people we love most — which means the bar is full disclosure, third-party verification, and clinical right-dosing on every product, including Neuro+ LPC.
DHA contributes to the maintenance of normal brain function — an established nutritional relationship recognised within evidence-based dietary guidelines. Neuro+ LPC is built around that science.
Where to Buy Lysoveta in Malaysia, Singapore, Hong Kong, and Bangkok
The Lysoveta ingredient is delivered in Southeast Asia through Nutrascience Neuro+ LPC. Direct shipping is available to Malaysia, Singapore, Hong Kong, and Bangkok. Order at nutrascience.co/products/neuro-lpc.
Frequently Asked Questions About Lysoveta
What is Lysoveta made from? Lysoveta is derived from Antarctic krill and produced by Aker BioMarine. It is standardised to deliver omega-3s in the lysophosphatidylcholine (LPC) form — primarily LPC-DHA, with some LPC-EPA — recognised by the brain's MFSD2A transporter. It is the active brain-targeted ingredient in Nutrascience Neuro+ LPC.
Is Lysoveta the same as krill oil? No. Standard krill oil primarily delivers PC-DHA (phosphatidylcholine). Lysoveta is produced through additional processing to deliver LPC-bound omega-3s, a structurally distinct lysophospholipid form. The MFSD2A transporter does not treat these two forms the same way.
Does Lysoveta contain EPA as well as DHA? Yes. Lysoveta delivers both LPC-DHA and LPC-EPA, although the DHA component is the primary contribution. Both forms are recognised by the MFSD2A transporter, and recent research suggests LPC-EPA can also raise brain DHA levels through metabolic conversion.
Can Lysoveta replace fish oil? They serve different biological purposes. Fish oil supports systemic omega-3 levels. Lysoveta — as delivered in Nutrascience Neuro+ LPC — is specifically designed for brain-targeted DHA delivery via MFSD2A. Neuro+ LPC combines both pathways with Lysoveta and Revervia algal DHA.
Is there human clinical trial data on Lysoveta? The mechanistic evidence for LPC-DHA brain uptake is well-established in peer-reviewed science (Nguyen et al., 2014, Nature). Preclinical studies support the superiority of LPC-DHA over triglyceride-form DHA for brain enrichment (Sugasini et al., 2017, Scientific Reports). Direct human RCT data specific to Lysoveta remains an active research area, and Nutrascience publishes its evidence tiers transparently rather than overstating the current data.
Is Lysoveta suitable for vegans? No. Lysoveta is krill-derived and is not suitable for vegans, vegetarians, or individuals with shellfish allergies. Nutrascience Neuro+ LPC includes this disclosure on every product page.
Where can I buy Lysoveta in Malaysia, Singapore, Hong Kong, or Bangkok, Thailand? Lysoveta is available in Southeast Asia through Nutrascience Neuro+ LPC at nutrascience.co/products/neuro-lpc, with direct shipping to all four markets.
What is MFSD2A? MFSD2A is a transport protein embedded in the blood-brain barrier that facilitates the movement of LPC-form fatty acids — including the LPC-DHA delivered by Lysoveta in Nutrascience Neuro+ LPC — from the bloodstream into the brain. It was identified as the major DHA transporter at the BBB in a landmark 2014 Nature study by Nguyen et al.
Is LPC-DHA safe? LPC-DHA in the form of Lysoveta is a phospholipid complex derived from food-source krill. Standard supplement precautions apply: individuals on anticoagulant medication (e.g. warfarin) should consult a healthcare professional before use.
Is Neuro+ LPC halal certified? No. Nutrascience Neuro+ LPC contains krill-derived phospholipids (Lysoveta) and bovine gelatin capsules. We have not pursued halal certification. For personal religious guidance, please consult your trusted religious advisor.
Summary
The Lysoveta inside Nutrascience Neuro+ LPC is a formulation-level answer to a well-defined biological problem: standard DHA supplements, in their triglyceride form, are not efficiently transported across the blood-brain barrier via MFSD2A. Lysoveta delivers DHA primarily in the LPC form — the structure the MFSD2A transporter is built to accept.
The science behind this distinction is mechanistically solid and supported by peer-reviewed research. The broader clinical picture, including human randomised trial data, is an active area of investigation — and Nutrascience publishes its evidence transparently rather than overclaiming.
For anyone whose interest in omega-3 supplementation is specifically cognitive — not just general wellness — the molecular form of DHA is the central question. Nutrascience Neuro+ LPC is built around that answer.
Now shipping to Malaysia, Singapore, Hong Kong, and Bangkok, Thailand. Order Nutrascience Neuro+ LPC →
